IFNβ-1a in vivo treatment effect on CIS multiple sclerosis patients: peripheral blood mononuclear cells
Summary:
Analysis of PBMCs from patients with clinically isolated syndrome suggestive of multiple sclerosis (CIS) after 12 months of IFNβ-1a treatment. All patients exhibited a favorable response to IFN-β-1a treatment. Results provide insight into the role of endogenous IFN-β in the pathogenesis of MS.
GPL570:
[HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array
Citation:
Tao Y, Zhang X, Chopra M, Kim MJ et al. The role of endogenous IFN-β in the regulation of Th17 responses in patients with relapsing-remitting multiple sclerosis. J Immunol 2014 Jun 15;192(12):5610-7. PMID: 24850724
